Join

Compare · MO vs PRDS

MO vs PRDS

Side-by-side comparison of Altria Group Inc. (MO) and Pardes Biosciences Inc. (PRDS): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both MO and PRDS operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
  • MO is the larger of the two at $117.21B, about 178.3x PRDS ($657.5M).
  • MO has hit the wire 6 times in the past 4 weeks while PRDS has been quiet.
  • MO has more recent analyst coverage (19 ratings vs 3 for PRDS).
MetricMOPRDS
Company
Altria Group Inc.
Pardes Biosciences Inc.
Price
$70.16+0.80%
$2.19+1.39%
Market cap
$117.21B
$657.5M
1M return
-3.98%
-
1Y return
+18.94%
-
Industry
Medicinal Chemicals and Botanical Products
Medicinal Chemicals and Botanical Products
Exchange
NYSE
NASDAQ
IPO
2021
News (4w)
6
0
Recent ratings
19
3
MO

Altria Group Inc.

Altria Group, Inc., through its subsidiaries, manufactures and sells cigarettes, oral tobacco products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. The company also produces and sells varietal and blended table wines, and sparkling wines under the Chateau Ste. Michelle and 14 Hands names; and imports and markets Antinori, Torres, and Villa Maria Estate wines, as well as Champagne Nicolas Feuillatte in the United States. In addition, it provides finance leasing services primarily in transportation, power generation, real estate, and manufacturing equipment industries. The company sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

PRDS

Pardes Biosciences Inc.

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.

Latest MO

Latest PRDS